GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) has earned a consensus rating of “Hold” from the nineteen analysts that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $56.30.
Several brokerages recently commented on GSK. Weiss Ratings restated a “hold (c+)” rating on shares of GSK in a research report on Tuesday, October 27th. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. HSBC reissued a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $67.40 to $55.90 in a report on Thursday, October 29th. Finally, Wall Street Zen lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st.
Get Our Latest Stock Report on GSK
Institutional Investors Weigh In On GSK
Large investors have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its position in GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after buying an additional 852,437 shares in the last quarter. Aberdeen Group plc bought a new position in GSK in the third quarter worth approximately $28,098,000. Equity Investment Corp boosted its holdings in GSK by 8.9% in the third quarter. Equity Investment Corp now owns 3,560,824 shares of the pharmaceutical company’s stock worth $171,525,000 after acquiring an additional 291,059 shares in the last quarter. Waverly Advisors LLC boosted its holdings in GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock worth $15,233,000 after acquiring an additional 270,863 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in GSK by 1,147.0% in the third quarter. Marshall Wace LLP now owns 288,988 shares of the pharmaceutical company’s stock worth $13,921,000 after acquiring an additional 265,814 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.
GSK Stock Performance
GSK stock opened at $47.75 on Friday. The stock has a 50-day moving average price of $49.31 and a 200-day moving average price of $52.33. GSK has a 1-year low of $45.83 and a 1-year high of $61.69. The company has a current ratio of 0.86, a quick ratio of 0.56 and a debt-to-equity ratio of 1.18. The firm has a market cap of $96.59 billion, a PE ratio of 16.59, a price-to-earnings-growth ratio of 2.27 and a beta of 0.29.
GSK Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be paid a dividend of $0.4518 per share. This is a boost from GSK’s previous quarterly dividend of $0.4515. This represents a $1.81 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend is Friday, November 13th. GSK’s payout ratio is currently 61.81%.
About GSK
GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.
See Also
- Five stocks we like better than GSK
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
